anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
The invention discloses an enzymolysis method of ovalbumin, comprising the following steps: (1) ovalbumin, papaya peplidase, L-cysteine and distilled water are uniformly mixed to carry out an enzymolysis reaction, wherein amino acid sequence of papaya peplidase is sequence as shown in SEQ ID NO:1; (2) a mixture obtained after enzymolysis in the step (1) is heated, and ovalbumin residue which hasn&#39;t undergone enzymolysis is filtered and removed; and (3) enzymolysis products obtained after processing in the step (2) are sterilized. Simple, low-cost and high-purity extraction of papaya peplidase from papaya latex is realized. In addition, papaya peplidase is a natural biologically-active substance. By the use of the peptidase for enzymolysis of ovalbumin, low-molecular oligopeptides and amino acid with molecular weight being 500-1000 can be obtained. The enzymolysis rate is high. The low-molecular oligopeptides and amino acid can be used as medicines for treating hepatopathy and also can further promote absorption of organisms and skin.
NEW MATERIAL:Isothiazolo[5,4-b]- or pyrazolo[3,4-b]-1,8-naphthylidine derivative of formula I (Q is S or NR&#39;; R is lower alkyl; R&#39; is lower alkyl), and their salt. EXAMPLE:8-Ethyl-5,8-dihydro-5-oxoisothiazolo[ 5,4-b ]1,8-naphthylidine-6-carboxylic acid ethyl ester. USE:Antibacterial agent having comparable activity to pipemidic acid, and effective to gram-negative and gram-positive bacteria. PROCESS:A compound of formula I is prepared by the acid- or alkalihydrolysis of a compound of formula III which is obtained either by heating a compound of formula II, amonia, and S in a polar solvent (e.g. ethyl alcohol) or by heating a compound of formula II and an alkyl hydrazine. The compound of formula I may be used in tne form of an alkali metal salt, etc. by conventional process.
NEW MATERIAL:A compound expressed by formula I (R&lt;1&gt; and R&lt;2&gt; are H or 1-3C alkyl), acid addition salt thereof and alkali salt thereof. EXAMPLE:5,6-Dihydro-1,2-dioxo-4H-pyroro[3,2,1-ij] guinoline-8-acetic acid ethyl ester. USE:An antirheumatic agent exhibiting no cyclooxygenase inhibiting action and being also excellent in safety and having bone breakage suppressing action. PREPARATION:A novel compound expressed by formula II (R is H or 1-3C lower alkyl) is hydrolyzed and as necessary subjected to decarbonylation in the presence of an oxidizing agent (e.g. hydrogen peroxide solution or peracetic acid) to provide the compound expressed by formula I. The reaction is preferably carried out at 0-50 deg.C for 30min-3hr.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a photoresponsive liposome controllable of the encapsulation and the release of a substance by reversibly varying the film form of the liposome, and a method for transporting a substance utilizing the same.  &lt;P&gt;SOLUTION: The photoresponsive liposome is formed by dispersing an azobenzene lipid and a phospholipid into a tris-hydrochloric acid buffer solution. The phospholipid has a gel-liquid crystal phase transition temperature of lower than the use temperature (for example, room temperature) of the liposome. The liposome enables reversible formation or disappearance of film pores on the film by irradiation with different types of light at different timing. The azobenzene lipid is preferably KAON. Through these film pores, a substance such as a drug can be encapsulated within the film of the liposome or released outside the film.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
PURPOSE:To improve observation shadow reading of a medical image, and a diagnostic function by providing information for determining a relative image display position on the medical image, and relating the photographing direction and a photographing means of the medical image in a specific examination of a body to be examined, and the relative image display position. CONSTITUTION:Image data of a medical image generated by an image collecting device 11, and its examination information and image incidental information are stored in a data base (DB) 12. Subsequently, when a patient&#39;s ID number is inputted from an input device 36 of a work station (WS) 13. Its ID is sent out to the DB 12, and the DB 12 transfers desired inspection information to the WS 13. Next, the WS 13 displays the inspection information as a patient&#39;s examination history to a character display device 37. In such a state, when an examination for shadow reading is designated, image incidental information and image data of a shadow reading object examination are transferred to the WS 13 from the DB 12. Subsequently, by a display position specifying means in an examination information/image incidental information storage device 39, a display position of each medical image is determined and displayed on an image display device 38.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a water-erodible pharmaceutical delivery device exhibiting good adhesion and localized drug delivery capability without giving patients minimal discomfort, a necessity in this field.  &lt;P&gt;SOLUTION: The pharmaceutical delivery device includes a layered film having a first water-erodible adhesive layer arranged to contact the mucosal surface and a second water-erodible non-adhesive backing layer containing hydroxypropyl cellulose and an alkyl cellulose. The device may have drugs included in the first layer, the second layer and both. The alkyl cellulose is ethyl cellulose. The ratio of hydroxypropyl cellulose to ethyl cellulose is 1,000:1-3:1.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an antibody, a peptide, a method and a composition for carrying out passive immunization of individual for treatment of infection of hepatitis C virus (HCV).  &lt;P&gt;SOLUTION: The hypervariable region (E2HV) of the putative hepatitis C virus (HCV) glycoprotein E2/NS1, between about amino acid 384 to about amino acid 414, is a rapidly evolving region of HCV, and is likely to be under positive immune selection. A newly discovered motif within this hypervariable region is immunogenic and conserved with respect to the character of the amino acids. In many isolates, this motif falls between amino acids 401 to 406 or 407. The discovery of this motif allows for additional materials and methods to treat and diagnose HCV.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
PROBLEM TO BE SOLVED: To produce a sheet-formed cosmetic useful for preventing the aging of the skin by effectively utilizing the shell of an egg such as hen&#39;s egg and forming the shell in the form of a sheet. SOLUTION: A water-soluble shell membrane produced by the treatment of a shell membrane of an avian egg with an acid, alkali, oxidizing agent, reducing agent, enzyme, etc., is used in the form of a sheet. The cosmetic material can be produced e.g. by forming a sheet from the soluble shell membrane or a mixture of the shell membrane with an excipient, etc., or applying the soluble shell membrane to the surface of a sheet material other than the shell membrane by lamination, coating, etc. Especially the latter cosmetic material is preferable owing to its high strength, etc. The other sheet material to be used in the above process as a substrate is e.g. a flexible sheet material such as polyethylene or polyvinyl alcohol or a woven cloth made of silk, rayon, polyester, polyurethane, etc.  The sheet cosmetic is brought into close contact with the face, abdomen, back, etc., for 5-60 minutes and the operation is performed at a frequency of thrice a week for &gt;=1 month to attain a good effect.
Recombinant protein from Nannochloropsis gaditana. The present invention relates to the use of a recombinant protein as an inhibitor of tumor growth, specifically to the use of the recombinant protein UCA01, which is a protein that immerses the cell in a period of mitotic inactivity in the case of tumor cells. In this way, it prevents tumor growth, in addition to preventing its appearance. UCA01 prevents tumor development due to three factors, its antioxidant capacity, increased activity of the p53 protein, and protection from mitochondrial degradation. Specifically, in the present invention the biological activity of the recombinant UCA01 protein extracted from the microalga (N. gaditana) is demonstrated for the first time. It is noted that the wild-type UCA01 protein was, prior to the present invention, initially classified as &#34;hypothetical protein&#34; in the NCBI (Accession: XM_005854224.1). (Machine-translation by Google Translate, not legally binding)
PROBLEM TO BE SOLVED: To obtain an aerosol composition having and excellent deodrizing effect, comfortable natural dry touch and stability. SOLUTION: This aerosol composition contains 0.01-20wt.% of aluminum octenylcinnamic acid corn starch ester and 0.01-20wt.% of an inorganic powdery material comprising a water-soluble metal salt (e.g. chlorohydroxy aluminum). The aerosol composition further contains 0.01-20wt.% of a spherical silicone resin having an average particle diameter of 1.0-10μm, 0.01-10wt.% of a nonionic surfactant having an HLB of &lt;8, and 5-99wt.% of a propellant (e.g. liquified gas). The aerosol composition may further suitably contain one or more kinds of known compounds such as a sterilizer, oils and fats, a wax, a silicone compound, an antiseptic, a UV light absorbent, a chelating agent, a humectant, a thickener, water, a refreshing agent, an antiinflammatory agent, an amino acid, a plant extract and a clathrate compound.
There is disclosed a slow release drug delivery device for the prolonged administration of topically active medicines which consists of a vehicle in which water is soluble and in which is dissolved the topically active drug which is formed into a stable organogel with a polymer matrix with a very low water absorbing capability. The organogel, in the presence of water or atmospheric water vapor, slowly imbibes such water into the vehicle and by doing so the vehicle becomes incompatible with the matrix and is slowly expelled therefrom. The vehicle dissolves the drug and the vehicle/drug combination is slowly pumped out of the polymeric matrix with substantially linear drug delivery occurring for periods in excess of 6 months. The drug delivery device may be used to administer drugs topically, as a collar or trans dermal patch, orally, as a slow delivery device, particularly as a ruminal bolus,, or as a suppository or a subcutaneous implant. The preferred form for the drug delivery device is as a flea and tick collar for household pets and the preferred active drug is selected from the avermectin and milbemycin families of active antiparasitic agents. &lt;IMAGE&gt;
PURPOSE:To obtain the titled substance useful as an intermediate for synthesiz ing a compound useful as an antimicrobial agent simply in high yield, by using an aniline as a raw material, reacting it with an alkoxymethylene malonic acid dialkyl ester, etc., and denitrating and subjecting the reaction product to ring formation simultaneously. CONSTITUTION:A compound shown by the formula I (X and Y are halogen; Z is group shown by the formula II, or formula III; R&lt;1&gt; and R&lt;2&gt; are H, or lower alkyl; R&lt;3&gt; is H, lower alkyl, lower acyl, lower alkoxycarbonyl, etc.; R&lt;4&gt; is H, lower alkyl, etc.; R&lt;5&gt; is H, lower alkyl, etc.) is reacted with an alkoxymethylene malonic acid dialkyl ester or a mixture of a orthoformic ester and a malonic acid dialkyl ester, to give a compound shown by the formula IV (R is lower alkyl). Then, this compound is heated in the presence of a catalyst, denitrated and sumultaneously subjected to ring formation to give a compound shown by the formula V. The compound shown by the formula I is a novel compound, and it is synthesized from a compound shown by the formula VI as a starting raw material through several processes.
Device, system and method to monitor user breathing patterns utilizing posture and diaphragm (breathing) sensor signals. The user worn device comprises a housing attached to a retractable belt that is worn around the user&#39;s trunk. The housing contains both posture and breathing sensors. The device monitors the output signals of these sensors and measures the state of both the user&#39;s posture and diaphragm (e.g. changes in the belt&#39;s length or force on the belt as a function of user breathing) to analyze breathing signals. The system&#39;s processor receives, processes, and transmits sensor signal data, and can also calibrate and interpret these signals utilizing various algorithms. In a preferred embodiment, the posture sensor is an accelerometer, and the retractable belt winds around a spring tensioned spool in the device&#39;s housing. The software can produce posture adjusted user respiration data, and can also be used for breath training and other purposes.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a skin beautifying agent that manifests tyrosinase-inhibiting activity and exhibits good skin-beautifying effects based on the activity.  &lt;P&gt;SOLUTION: The skin beautifying agent includes Dunaliella tertiolecta exhibiting tyrosinase-inhibiting activity. A dried frond of Dunaliella tertiolecta is obtained by freeze-drying cultivated cells that are obtained by cultivating cells of Dunaliella tertiolecta. Extracts of Dunaliella tertiolecta is prepared by adding an extracting solvent to the dried fond of Dunaliella tertiolecta prepared by the freeze-drying, agitating the mixture to extract effective ingredients, and freeze-drying the extracts. The tyrosinase-inhibiting activities are directly exhibited by applying it on the skin. As the compounding agent for beautifying the skin, at least collagen is incorporated with Dunaliella tertiolecta.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
Fractures, breaks and nonunions of bones are more readily healed without muscle atrophy, etc., by injecting a liquefied composition containing a non-necrotic vascular sclerosing agent into the site of the fracture or nonunion. No cast is used. The preferred non-necrotic vascular sclerosing agent is sodium oleate. Bones can be fused together by injecting a liquefied composition containing a non-necrotic vascular sclerosing agent into the interface region between the bones. Normally a cast or brace is not used. The preferred non-necrotic vascular sclerosing agent is sodium oleate. Splints and diffused splints can be prepared using the bone fusing technique. Splints, ringbone, bucked shins and osslets can be treated according to this invention. This invention also involves stopping and reversing demineralization which has occurred around screws, pins and other metal inserts which have been placed in bones. The demineralized region is caused to &#39;&#39;&#39;&#39;heal&#39;&#39;&#39;&#39; in that healthy bone results upon the injecting of at least one dosage of a liquefied composition containing a non-necrotic vascular sclerosing agent into the site of the demineralization. The preferred non-necrotic vascular sclerosing agent is sodium oleate. The process is normally used to treat demineralization resulting from screws which have been inserted in fractured bones. Before, during and after the above treatment is completed, the fractures and nonunions of bones can more readily be healed without muscle atrophy, etc, by injecting a liquefied composition containing a non-necrotic vascular sclerosing agent (e.g., sodium oleate) into the site of the fracture or nonunion.
It is disclosed a method (100) for operating an electrosurgical generator (10) and an according electrosurgical generator. The electrosurgical generator is configured to supply power to an electrosurgical instrument (11). The electrosurgical generator is identifiable by a serial number (12) and comprises at least two modules (20, 20&#39;). The modules (20, 20&#39;) are embodied as hardware modules and/or as software modules. Each of the modules has a functionality according to an operation mode which is at least partially specified by a license key. In an initializing process of the electrosurgical generator, identification information being indicative of a serial number (12) is available or is made available (101) at at least one of the modules and license information being indicative of a license key is available or is made available (102) at at least one of the modules. Each of the modules provides (103) any of the identification information and the license information being available or being made available to it to at least one other of the modules. At least one of the modules generates (104) a link of the identification information and the license information and provides (105) the generated link to each of the other modules. Each of the modules stores (106) the generated link. The invention provides a beneficial method for operating an electrosurgical generator, which makes use of an existing modular design of the generator to provide the modules of the electrosurgical generator with information about a customized scope of functionality for them to provide.
PROBLEM TO BE SOLVED: To obtain a solid powdery make-up cosmetic having excellent make-up durability even under severe condition such as perspiration by compounding a specific substance together with hydrophobicized powder. SOLUTION: A water-swelling clay mineral is used together with powder subjected to hydrophobic treatment. The water-swelling clay mineral is preferably colloidal hydrated aluminum silicate ordinarily used as a preparation for external use for skin. Concrete examples of the clay mineral are montmorillonite, beidellite, nontrollite, saponite, hectorite, etc. The amount of the clay mineral to be compounded to the solid powdery make-up cosmetic is &gt;=1%, especially 4i2%, most preferably &gt;=5% and up to about 50%. The hydrophobicized powder is obtained by the hydrophobia treatment of, e.g., talc, kaolin, sericite, calcium carbonate, zinc white, titanium-coated mica or bismuth oxychloride. The hydrophobicizing treatment is, e.g., a high-viscosity silicone oil treatment or a fluorine treatment.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide transgenic animals producing humanized monoclonal antibodies and humanized monoclonal antibodies produced therefrom.  &lt;P&gt;SOLUTION: They are transgenic non-human animals operated so as to contain human immunoglobulin gene loci. In particular, animals in accordance with the invention possess human Ig gene loci that include a plurality of variable (VH and Vκ) genes regions. Advantageously, the inclusion of a plurality of variable region genes enhances the specificity and diversity of human antibodies produced by the animal. Further, the inclusion of such regions enhances and reconstitutes B-cell development to the animals, such that the animals possess abundant mature B-cells secreting extremely high affinity antibodies.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
A method for utilizing an individual&#39;s undifferentiated papilla and/or bulge area stem cells to stimulate hair growth. The inventor has discovered that bulge area stem cells can be harvested, isolated, cloned, and successfully transplanted into an area of the donor&#39;s skin where increased growth of hair is desired to increase hair growth therein. In the first step of the method, a donor section of skin is identified having growth of the type of hair for which increased growth at the recipient site is sought. Since hair types differ according to their anatomical site, it is generally desirable to match the hair produced by the donor stem cells to the type of hair that is desired at the recipient site. For example, in treatment of male pattern baldness, tissue samples are harvested from an area of the scalp that still exhibits vigorous growth. Once the donor site is identified, it is anesthetized locally using any convenient means and a plurality of tissue samples are obtained from the donor site. The tissue samples preferably contain hair follicles with intact undifferentiated papilla and/or dermal stem cells, as well as immediately surrounding tissues. Any method of tissue sampling can be employed, for example, punch biopsy, so long as viable stem cells can be obtained. The stem cells are cloned to multiply the number of cells preferably by about 10 to 1,000 times or more. Some of the stem cells can be frozen for later use. Some of the stem cells are inserted into skin regions where hair restoration is desired. Various techniques are disclosed for inserting the stem cells into the skin.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an adjuvant composition suitable to be used in a vaccine.  &lt;P&gt;SOLUTION: The adjuvant composition of the present invention especially contains a saponin and an immunostimulatory oligonucleotide optionally in combination with a carrier. Also provided by the present invention are vaccines containing the adjuvants of the present invention and an antigen. Further provided are methods of manufacture of the adjuvants and vaccines of the present invention and their use as medicaments. Methods of treating an individual susceptible to or suffering from a disease by the administration of the vaccines of the present invention are also provided.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
The invention discloses a Chinese medicinal composition for treating periodontitis. Traditional Chinese medical science considers that the periodontitis belongs to the category of &#39;gingival atrophy&#39; and &#39;toothache&#39;, and the pathogenesis is excessive pathogenic fire or hyperactivity of deficiency fire. Clinical researches conducted by the hospital in recent years indicate that on the basis of the therapeutic principle of clearing stomach and reducing pathogenic fire, detoxicating and reliving swelling, cooling blood and stopping bleeding, eliminating blood stasis and dredging collaterals and nourishing yin and tonifying kidney, the Chinese medicinal composition has a good treatment effect. Decoction is prepared from bupleurum, golden thread, liquoric root, Mongolian dandelion herb, platycodon root, Szechuan lovage rhizome, Chinese arborvitae twig, cortex moutan, peach seed, Chinese angelica, white paeony root, prepared rehmannia root, cinnamomvine and medlar. Clinical trials prove that: the cure rate is 82.4 percent, the effective rate is 96.3 percent and is obviously higher than that of a control group. In addition, the Chinese medicinal composition does not have toxic or side effect, and is high in anti-inflammatory capacity, quick in detumescence and safe and reliable in a curative effect.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an anticancer activity enhancer for anticancer agents containing anti-MRP1 antibody.  &lt;P&gt;SOLUTION: An RNA is prepared from 38 example lung cancer-derived cell lines, 3 example normal fibroblast lines, 43 example lung cancer clinical specimens and 6 example normal lung tissues, and after fluorescent labeling of the RNA, a hybridization is carried out for a slide immobilized with 7685 kinds of gene fragments. As a result of carrying out an ordinary hierarchical clustering, all of the cell lines and the clinical specimens are separated to respectively different clusters. Regarding that a gene expression profile reflecting respective disease types may be obtained by excluding genes that are highly expressed or decline in expression commonly in the cultured cell lines or the clinical specimens respectively, a filtering method enabling the above is newly devised and carried out. As a result, a disease type-specific gene expression profile can be obtained, and MRP1 is screened as being increasedly expressed specifically to flat epithelial lung cancer.  &lt;P&gt;COPYRIGHT: (C)2004,JPO